Doximity (DOCS) Advances While Market Declines: Some Information for Investors
Doximity (DOCS) closed at $20.89 in the latest trading session, marking a +1.02% move from the prior day.
Doximity (DOCS) Up 11.2% Since Last Earnings Report: Can It Continue?
Doximity (DOCS) reported earnings 30 days ago. What's next for the stock?
Dr Martens profits jump as turnaround gains grip
Dr Martens PLC (LSE:DOCS) returned to profit growth last year as the bootmaker tightened discounting, improved margins and pushed ahead with a turnaround centred on higher-quality sales. The FTSE 250-listed group reported an adjusted pre-tax profit of £55 million in the year to 29 March, up 61% on the year before, while revenue fell 2.9% to £764.9 million.
DOCS vs. HIMS: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical Info Systems sector have probably already heard of Doximity (DOCS) and Hims & Hers Health, Inc. (HIMS). But which of these two companies is the best option for those looking for undervalued stocks?
DOCS Teams Up With Aledade to Bring Clinical AI to Value-Based Care
Doximity teams with Aledade to bring AI-powered documentation and clinical search tools into physician workflows and value-based care settings.
Doximity Earnings: Strong AI Signals, But Monetization Still Pending
Doximity, Inc. delivered mixed FY26 results, with solid revenue growth but margin compression and a cautious near-term outlook. AI-driven engagement is accelerating, with rapid adoption of clinical tools and strong enterprise traction, but monetisation lags due to regulatory and operational friction. FY27 is positioned as a transition year, with guidance for just 4% revenue growth and EBITDA margin compression as AI investments ramp.
Down 25.7% in 4 Weeks, Here's Why Doximity (DOCS) Looks Ripe for a Turnaround
Doximity (DOCS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Doximity Stock Falls on Q4 Earnings Miss, Revenues Beat, Margins Down
DOCS' revenues top estimates as AI tool adoption and large customer growth fuel engagement despite weaker earnings and margin pressure.
Doximity, Inc. (DOCS) Q4 2026 Earnings Call Transcript
Doximity, Inc. (DOCS) Q4 2026 Earnings Call Transcript
Doximity Q4 Earnings Call Highlights
Doximity NYSE: DOCS reported fiscal fourth-quarter revenue above the high end of its guidance and said it is entering what management called an “AI investment year,” with higher spending planned for artificial intelligence products even as near-term growth in the digital pharma advertising market remains soft.
Doximity (DOCS) Lags Q4 Earnings Estimates
Doximity (DOCS) came out with quarterly earnings of $0.26 per share, missing the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.38 per share a year ago.
Insights Into Doximity (DOCS) Q4: Wall Street Projections for Key Metrics
Besides Wall Street's top-and-bottom-line estimates for Doximity (DOCS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2026.
